Macrogenics (MGNX) Misses Q2 EPS by 11c, Misses on Revenue

Macrogenics (NASDAQ: MGNX) reported Q2 EPS of ($0.57), $0.11 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $22.2 million versus the consensus estimate of $28.06 million.

For earnings history and earnings-related data on Macrogenics (MGNX) click here.

You May Also Be Interested In

• UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
• UBS Starts Assembly Biosciences (ASMB) at Buy
• RBC Capital Resumes BorgWarner (BWA) at Outperform